Global Acute Migraine Drugs Market is Segmented By Type (Triptans, NSAIDs, Others), By Route of Administration(Oral, Injectable, Nasal sprays, Others), By End -User (Hospital Pharmacies, Drug Stores), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Acute Migraine Drugs Market Overview
Global Acute Migraine Drugs Market reached US$ 10.1 billion in 2022 and is expected to reach US$ 18.6 billion by 2030 growing with a CAGR of 8.1% during the forecast period 2024-2031. The global acute migraine drugs market is driven by the factors such as the increasing prevalence of migraine, rising demand for innovative drugs, increasing awareness and diagnosis, and technological advancements in acute migraine drugs.
The global acute migraine drugs market is a rapidly growing sector within the pharmaceutical industry. Migraine is a prevalent neurological disorder affecting millions of people worldwide, driving the demand for effective treatment options including drugs. The market primarily consists of various drug classes, including triptans, ergot alkaloids, NSAIDs, and among others, which are commonly used to alleviate acute migraine symptoms.
Acute Migraine Drugs Market Scope
| Metrics | Details |
| CAGR | 8.1% |
| Size Available for Years | 2021-2030 |
| Forecast Period | 2024-2031 |
| Data Availability | Value (US$) |
| Segments Covered | Drug Type, Route of Administration, Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Infection Type Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
To know more Insights Download Sample
Acute Migraine Drugs Market Dynamics
Rising Demand for Innovative Drugs Drives the Growth of the Acute Migraine Drugs Market
Ongoing research and advancements in the understanding of migraine pathophysiology have identified new potential targets for drug development like the role of calcitonin gene-related peptide (CGRP) in migraine has led to the development of CGRP inhibitors, which have shown promising results in clinical trials. The growing knowledge of the underlying mechanisms of migraines opens up opportunities for the development of innovative drugs.
Moreover, despite the availability of existing acute migraine drugs, there are still significant unmet medical needs in terms of efficacy, tolerability, and safety. Many individuals with migraines do not achieve satisfactory relief from their symptoms or experience undesirable side effects with current treatment options. This creates a demand for innovative drugs that can provide better outcomes and improve the overall patient experience.
For instance, on April 17, 2023, IntelGenx Corp., a leader in pharmaceutical films, announced that the U.S. Food and Drug Administration has approved the Company’s RIZAFILM VersaFilm new drug application for the treatment of acute migraine. RIZAFILM is a proprietary oral thin film formulation of rizatriptan benzoate, the active ingredient in Merck & Co.'s Maxalt.
Increasing Awareness and Diagnosis Also Drive the Growth of the Acute Migraine Drugs Market
Increasing awareness of migraines as a neurological disorder helps individuals recognize and understand their symptoms better. This awareness encourages people to seek medical attention and obtain a proper diagnosis for their condition. As more individuals are diagnosed with migraines, the demand for effective treatment options, including acute migraine drugs, increases.
Patient advocacy groups and organizations play a significant role in raising awareness of migraines and providing support for better access to treatment. These groups help educate the public about migraines, promote research, and work towards reducing the condition. Their efforts contribute to an environment where more individuals are diagnosed and seek appropriate treatment, thereby driving the demand for acute migraine drugs.
Side Effects Associated with Drugs Will Hamper the Growth of the Market
Acute migraine drugs can have side effects and safety concerns. Some patients experience adverse effects such as dizziness, drowsiness, or gastrointestinal disturbances. Safety concerns arise with the long-term use of certain drugs or the potential for drug interactions. These factors influence patient compliance and limit the market growth.
Side effects experienced by patients impact their compliance and persistence with the prescribed medication. If individuals encounter significant adverse effects, they may discontinue or reduce the use of the medication, leading to suboptimal treatment outcomes. This limits the market growth as patients seek alternative treatment options or discontinue using the drugs.
Acute Migraine Drugs Market Segment Analysis
The global acute migraine drugs market is segmented based on drug type, route of administration, distribution channel, and region.
The Triptans Segment Accounted for Approximately 36.8% of the Acute Migraine Drugs Market Share
Triptans have been widely used for many years and have demonstrated consistent efficacy in relieving migraine symptoms, such as pain, nausea, and sensitivity to light and sound. They work by constricting blood vessels and inhibiting the release of inflammatory substances in the brain associated with migraines. Their established effectiveness has built trust among healthcare providers and patients, contributing to their continued dominance in the market.
For instance, on June 26, 2023, Tonix Pharmaceuticals Holding Corp. and its wholly-owned subsidiary Tonix Medicines, Inc., a clinical-stage biopharmaceutical company, announced that they have entered into an agreement to acquire two currently-marketed products from Upsher-Smith Laboratories, LLC Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg. Zembrace SymTouch and Tosymra are both indicated for the treatment of acute migraine with or without aura in adults.
Triptans are well-established in clinical practice and are recommended as first-line treatment options in various treatment guidelines for migraines. Physician preference and adherence to treatment guidelines influence prescribing patterns, further supporting the dominance of triptans in the market.
Source: DataM Intelligence Analysis (2023)
Acute Migraine Drugs Market Geographical Penetration
North America Accounted for Approximately 40.2% of the Market Share in 2022, Owing to the Strong Research and Developments and Advanced Healthcare Infrastructure
North America boasts a well-developed and advanced healthcare infrastructure, including hospitals, clinics, and a network of healthcare providers. This infrastructure facilitates timely diagnosis, access to specialized care, and effective management of acute migraine. The presence of specialized headache centers and neurology clinics enhances the diagnosis and treatment of migraines, leading to higher demand for acute migraine drugs.
North America is a hub for pharmaceutical research and development, with numerous pharmaceutical companies and academic institutions conducting extensive research in the field of migraine and drug development. This focus on innovation and clinical trials contributes to the availability of a wide range of acute migraine drugs in the market leading to market dominance in the region.
For instance, on May 18, 2023, Satsuma Pharmaceuticals, Inc., a development-stage biopharmaceutical company announced that its new drug application (NDA) for STS101, a novel and investigational therapeutic product candidate for the acute treatment of migraine, has been accepted for review by the FDA.
Source: DataM Intelligence Analysis (2023)
Acute Migraine Drugs Market Competitive Landscape
The major global players in the acute migraine drugs market include Teva Pharmaceuticals, F Hoffmann-la Roche Ltd, Johnson & Johnson, Pfizer Inc., AstraZeneca, Amgen Inc., Merck & Co., Novartis AG, Eli Lilly and Company, and Sun Pharma among others.
COVID-19 Impact on Acute Migraine Drugs Market
The COVID-19 pandemic significantly impacted the global acute migraine drugs market. The pandemic led to disruptions in healthcare services, including reduced access to medical facilities, postponement of non-emergency appointments, and diversion of resources to manage COVID-19 patients. As a result, many individuals with migraines may have faced challenges in obtaining timely medical care, including the prescription and administration of acute migraine drugs.
Russia Ukraine Conflict Analysis
The Russia-Ukraine conflict is estimated to have a moderate impact on the global acute migraine drugs market. The Russia-Ukraine conflict can have an impact on investment in research and development activities. Pharmaceutical companies may face difficulties in securing funding or allocating resources to R&D initiatives, potentially affecting the development of new acute migraine drugs or innovative treatment options.
By Drug Type
- Triptans
- NSAIDs
- Ergot Alkaloids
- Others
By Route of Administration
- Oral
- Parenteral
- Nasal
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
- Middle East and Africa
Key Developments
- On March 10, 2023, Pfizer Inc. announced the U.S. Food and Drug Administration has approved ZAVZPRET (zavegepant), the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults. In its pivotal Phase 3 study, ZAVZPRET was statistically superior to placebo on the co-primary endpoints of pain freedom and freedom from most bothersome symptoms at two hours post-dose. The pivotal study also demonstrated pain relief as early as 15 minutes in a prespecified secondary endpoint versus placebo.
- On February 12, 2023, Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it has acquired rights to ELYXYBTM (celecoxib oral solution) in the U.S. and Canada, the only FDA-approved ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.
Why Purchase the Report?
- To visualize the global acute migraine drugs market segmentation based on drug type, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of acute migraine drugs market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global acute migraine drugs market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
For more Pharmaceuticals related reports, please click here
